| Literature DB >> 30420600 |
Xianrong Lai1,2, Dong Tong3, Xiaopeng Ai3, Jiasi Wu3, Yu Luo3, Fang Zuo3, Zhicheng Wei3, Yanqiao Li3, Wanyi Huang3, Wenqian Wang3, Qing Jiang3, Xianli Meng3, Yong Zeng3, Ping Wang3.
Abstract
Siwei Jianghuang Decoction Powder (SWJH) documented originally in the Four Medical Tantras-Blue Glaze exhibited beneficial effects on diabetic nephropathy (DN) via combined synergistically action of multiple formula components including Curcumae longae Rhizoma, Berberidis dictyophyllae Cortex, Phyllanthi Fructus and Tribuli Fructus. This study investigated the effects of SWJH on DN in db/db mice and possible underlying mechanisms. The ten weeks old db/db mice treated with SWJH by intra-gastric administration once a day for 8 weeks. After 8 weeks, body weight, water and food intake of mice were recorded. The level of fasting blood glucose (FBG) was measured. Serum creatinine (Scr), blood urea nitrogen (BUN), urine microalbumin (UMAlb), serum uric acid (UA) and urinary albumin excretion (UAE) were detected. An enzyme-linked immunosorbent assay was performed to test serum vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1). Real-time PCR and Western blot analysis were used to test mRNA and protein expression of hypoxia inducible factor-1α (HIF-1α), VEGF and TGF-β1 in kidney tissue. SWJH treatment significantly reduced the levels of FBG, Scr, BUN, UMAlb, UA and UAE and retarded renal fibrosis. SWJH treatment further significantly reduced serum TGF-β1 level and downregulated the expression of HIF-1α, VEGF and TGF-β1 at both mRNA and protein levels. Principal component analysis and partial least squares regression and hierarchical cluster analysis demonstrated that SWJH treatment significantly ameliorated renal damage in DN mice. These consequences suggested that SWJH formulations were effective in the treatment of DN through regulating the HIF-1α, VEGF and TGF-β1 overexpression.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30420600 PMCID: PMC6232159 DOI: 10.1038/s41598-018-35148-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Technical roadmap of amelioration of DN in db/db mice treated with tibetan formula Siwei Jianghuang extract.
Figure 2HPLC chromatogram for SWJH (A) and mixed reference substance (B). 1. gallic acid; 2. magnoflorine; 3. ellagic acid; 4. Jatrorrhizine hydrochloride; 5. palmatine hydrochloride; 6. berberine hydrochloride; 7. curcumin.
Primers list for real-time PCR analysis.
| Gene | Forward 5′-3′ | Reverse 5′-3′ | Product length |
|---|---|---|---|
| HIF-1α | TTGCTTTGATGTGGATAGCGATA | CATACTTGGAGGGCTTGGAGAAT | 223 |
| TGF-β1 | CGAAGCGGACTACTATGCTAAAGAG | TGGTTTTCTCATAGATGGCGTTG | 77 |
| VEGF | GTAACGATGAAGCCCTGGAGTG | CACAGTGAACGCTCCAGGATTTA | 243 |
| GAPDH | AGGAGCGAGACCCCACTAACA | AGGGGGGCTAAGCAGTTGGT | 247 |
Biochemical data of all groups.
| Groups | db/m | db/db | Metformin (0.196 g/kg) | SWJH (0.978 g/kg) | SWJH (1.957 g/kg) | SWJH (3.914 g/kg) | Berberine (0.157 g/kg) |
|---|---|---|---|---|---|---|---|
| Body weight (g) | 25.2 ± 1.00** | 60.7 ± 3.50 | 58.9 ± 5.70 | 57.6 ± 2.43 | 53.3 ± 2.10** | 56.0 ± 2.80* | 56.5 ± 3.00* |
| Left kidney weight (g) | 0.17 ± 0.01** | 0.22 ± 0.01 | 0.18 ± 0.02** | 0.18 ± 0.03* | 0.18 ± 0.01** | 0.18 ± 0.02** | 0.18 ± 0.01** |
| FBG (mmol/L) | 6.0 ± 0.60** | 26.5 ± 1.90 | 17.9 ± 3.10** | 23.9 ± 4.00 | 18.9 ± 5.80* | 17.2 ± 7.90* | 17 ± 2.10** |
| BUN (mmol/L) | 4.6 ± 0.40** | 7.4 ± 1.1 | 6.1 ± 0.7* | 5.1 ± 0.4** | 4.6 ± 1.1** | 5.0 ± 0.7** | 4.7 ± 0.7** |
| UAE (mg/day) | 0.64 ± 0.04** | 5.04 ± 1.26 | 1.40 ± 0.73** | 1.69 ± 0.67** | 1.14 ± 0.45** | 0.78 ± 0.12** | 0.60 ± 0.33** |
| UMAlb (µg/day) | 9.5 ± 1.7** | 63.6 ± 25.4 | 28.6 ± 16.7* | 20.9 ± 9.3** | 33.1 ± 20.4* | 18.8 ± 9.8** | 16.9 ± 3.8** |
| Scr (µmol/L) | 63.0 ± 5.9** | 147.8 ± 14.2 | 119.1 ± 5.0** | 124.4 ± 20.0* | 115.2 ± 7.6** | 118.9 ± 17.3* | 64.3 ± 14.8** |
| UA(µmol/L) | 66.3 ± 13.1** | 152.6 ± 41.1 | 75.9 ± 14.7** | 73.7 ± 31.6** | 101.2 ± 24.7* | 109.3 ± 43.9 | 96.6 ± 15.7* |
| TGF-β1 (×1000 pg/ml) | 6.2 ± 3.0** | 16.6 ± 5.8 | 6.5 ± 3.0** | 4.7 ± 0.9** | 5.4 ± 0.8** | 7.8 ± 3.0* | 5.3 ± 1.1** |
| VEGF (pg/ml) | 184.5 ± 17.2* | 205.7 ± 5.9 | 212.0 ± 22.8 | 179.2 ± 28.8 | 224.7 ± 25.7 | 197.1 ± 34.1 | 188.1 ± 17.3* |
Data expressed as mean ± SD, *P < 0.05, **P < 0.01 compared with db/db group (n = 6).
Figure 3Effect of SWJH on renal histopathology and ultrastructural pathology. (H–N) H&E stain at 200× magnification. (A–G) PASM staining at 400× magnification. (O) Mean IOD of GBM in PASM staining. **P < 0.01 compared with db/db group (n = 6).
Figure 4Effect of SWJH on renal HIF-1α/VEGF/TGF-β1 expression. (A–U) Immunohistochemistry of HIF-1α, VEGF and TGF-β1. Original magnification (A–U) at 400× magnification; (A–C) Quantitative analyses of immunohistochemical staining of HIF-1α, VEGF and TGF-β1. *P < 0.05, **P < 0.01 compared with db/db group (n = 6).
Figure 5Effect of SWJH on renal HIF-1α, VEGF and TGF-β1 expression. Real-time PCR analyses of HIF-1α, VEGF and TGF-β1 mRNA levels. *P < 0.05, **P < 0.01 compared with db/db group (n = 6).
Figure 6Effect of SWJH on renal HIF-1α, VEGF and TGF-β1 expression. (A–D) Western blot analyses of HIF-1α, VEGF and TGF-β1 protein levels. **P < 0.01 compared with db/db group (n = 6).
Figure 7PCA (A) and PLS (B) for effect of SWJH.
Figure 8HCA by Dendrogram plot, Squared Euclidean and Ward’s method for effect of SWJH.